Clinical trials
Chronic Kidney Disease Stage 4 clinical trials
Below are recruiting chronic kidney disease stage 4 clinical trials, each written for real people, not researchers. We’re tracking 147 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04981509RecruitingPhase 2
Check if 3 medicines help advanced kidney cancer
This Phase 2 trial tests whether combining bevacizumab, erlotinib, and atezolizumab can shrink or control advanced kidney cancer. It’s aimed at people with certain kidney-cancer subtypes (including HLRCC-related cases or papillary kidney cancer) and who have not had many prior targeted or immune treatments.
La Jolla, CaliforniaAges 12 years+ - NCT06399419RecruitingPhase 1
Study of CBM588 with immunotherapy for advanced kidney cancer
This trial tests whether adding a probiotic (CBM588) to a standard immunotherapy combination (nivolumab and ipilimumab) helps treat advanced kidney cancer. It is for people with a specific type of kidney cancer that has spread or cannot be removed with surgery, who have not had systemic treatment before.
Duarte, CaliforniaAges 18 years+ - NCT05832229RecruitingPhase 2
Studying rosuvastatin to slow liver scarring in cirrhosis
This Phase 2 trial tests whether rosuvastatin (a cholesterol-lowering medicine) can improve how well the liver functions and slow worsening scarring in people with cirrhosis. It also checks for side effects and safety.
La Jolla, CaliforniaAges 18–75 - NCT06071429Recruiting
Dissolvable medicine stent for leg artery disease
This trial tests a new dissolvable stent that slowly releases medicine to keep your lower-leg artery open. It is for people with severe leg pain or small wounds due to poor blood flow, and who are not eligible for other stents.
New York, New YorkAges 18 years+ - NCT06291077RecruitingPhase 4
Belatacept vs anticalcineurins after kidney transplant
This study is comparing two medications after kidney transplant: Belatacept and anticalcineurins (like tacrolimus). It looks at how each affects blood vessel health. If you are more than a year post-transplant and have stable kidney function, you may be eligible.
RouenAges 18–75 - NCT07142252RecruitingPhase 2
New drug for recently diagnosed type 1 diabetes
This trial tests a new medicine (rezpegaldesleukin) to see if it can help preserve the body's ability to make some insulin in people recently diagnosed with type 1 diabetes. It's for children and adults diagnosed within the past 100 days.
Aurora, ColoradoAges 8–45 - NCT06708338Recruiting
Bevel direction during dialysis fistula puncture
This study looks at which way the needle bevel should face when starting dialysis through a new fistula. It might help reduce pain or damage to the fistula.
Le Puy-en-VelayAges 18–85 - NCT06173947Recruiting
SSM Score for Liver Injury in Chronic Liver Disease
This study looks at how well a simple score (called SSM) can predict recovery in people with chronic liver disease who suddenly get a liver injury with jaundice. It may help your doctors understand how serious your condition is.
Guangzhou, GuangdongAges 18–80 - NCT06341452Recruiting
Comparing custom salt levels vs. standard care in dialysis
This trial tests if adjusting the salt (sodium) in your dialysis fluid can improve your health. It is for people on dialysis who have trouble with too much fluid gain or high blood pressure between sessions.
Mariánské LázněAges 18 years+ - NCT06597201RecruitingPhase 4
Testing Amino Acid Dialysis Solution for Malnutrition on Peritoneal Dialysis
This trial tests a special peritoneal dialysis solution with amino acids (protein building blocks) to improve nutrition in people on CAPD who are malnourished. It might help boost your protein levels and overall health.
Hefei, AnhuiAges 18–75 - NCT06772454Recruiting
Testing a new drug combo for advanced lung cancer with COPD
This trial tests whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy and inhaled steroids helps people with advanced lung cancer who also have COPD. The goal is to see if this combination improves outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT07707271Recruiting
Continuous vs. interval exercise for COPD
This trial compares two types of exercise training—steady moderate exercise versus short bursts of higher intensity—to see which is more helpful for people with COPD. It aims to find a better way to improve your breathing and fitness.
Thessaloniki, ExohiAges Any age - NCT06976762Enrolling by invitation
Light-based muscle oxygen measurements in COPD with kidney disease
This study uses a special light-based device (near-infrared spectroscopy) to measure muscle oxygen levels in people who have both COPD and chronic kidney disease. Researchers want to see if these measurements can help predict how the disease progresses, which could lead to better monitoring and treatment.
Tokat ProvinceAges 18–80 - NCT06082063RecruitingPhase 3
Reducing heart disease risk in type 1 diabetes
This trial tests a combination of treatments to lower the risk of heart disease and kidney problems in people with type 1 diabetes who already have some complications or higher risk. If you qualify, you will receive extra care aimed at preventing heart attacks, strokes, and kidney failure.
CopenhagenAges 40–90 - NCT07221227RecruitingPhase 3
Testing a new drug for MASH with moderate scarring
This trial tests a new medicine called Efimosfermin Alfa for people with MASH (a fatty liver disease) and moderate liver scarring. It aims to see if the medicine can improve the liver condition.
Chandler, ArizonaAges 18–75 - NCT06525909Recruiting
Immune status in chronic hepatitis B
This study looks at how the immune system changes over time in people with chronic hepatitis B. It will help doctors better understand the stages of the disease to guide treatment decisions.
Wuhan, HubeiAges 18–50 - NCT04561557RecruitingEarly Phase 1
Cell therapy for relapsing nervous system autoimmune diseases
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
Wuhan, HubeiAges 18–75 - NCT06661720RecruitingPhase 3
Tivozanib and pembrolizumab after kidney cancer surgery
This trial is testing if adding the targeted therapy tivozanib to the immunotherapy drug pembrolizumab (Keytruda) can help prevent kidney cancer from coming back after all known tumors have been removed by surgery.
Phoenix, ArizonaAges 18 years+ - NCT06919003RecruitingPhase 2
Improving kidney transplant with a single injection of a protective protein
This trial tests whether a single injection of C1 esterase inhibitor into a donated kidney during preservation can improve transplant outcomes. It is for adults on dialysis waiting for a deceased-donor kidney who meet specific blood and tissue matching requirements.
Los Angeles, CaliforniaAges 18–75 - NCT04823923Recruiting
How kidney failure affects drug levels in metastatic kidney cancer
This study looks at how chronic kidney failure changes the amount of certain cancer medicines in the blood. It involves people with metastatic clear cell kidney cancer who take pazopanib or cabozantinib, and compares drug levels in different kidney function groups.
MarseilleAges 18 years+ - NCT07383441RecruitingPhase 3
Adding Biotherapy or Placebo to Standard Kidney Cancer Treatment
This trial tests whether adding a biotherapy (a special drug from a living source) or a placebo to standard treatments helps people with advanced kidney cancer. It may be a good option if your cancer hasn't been treated yet and you are in fairly good health.
Fayetteville, ArkansasAges 18 years+ - NCT05361720RecruitingPhase 2
Genetic test to match treatment for advanced kidney cancer
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
Duarte, CaliforniaAges 18 years+ - NCT06736665Recruiting
Comparing two ways to treat hardened calcium in heart arteries
This trial compares two techniques (orbital atherectomy and intravascular lithotripsy) to break up tough calcium deposits in the heart's arteries that can block blood flow. If you have a calcified nodule and are having a non-emergency procedure to open a blocked artery, this study may help guide which method works best.
Alicante, AlicanteAges 18 years+ - NCT06866262RecruitingPhase 1/Phase 2
Inulin gel with immunotherapy for advanced kidney cancer
This trial tests whether adding an inulin gel to standard immunotherapy (ipilimumab and nivolumab) can help treat kidney cancer that has spread or cannot be removed. It is for people who have not had prior treatment for advanced disease.
Ann Arbor, MichiganAges 18 years+
Hear when a new Chronic Kidney Disease Stage 4 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic kidney disease stage 4?
- Yes. Clin2 currently lists 147 recruiting chronic kidney disease stage 4 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic kidney disease stage 4 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic kidney disease stage 4 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.